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Abstract Patients with advanced breast cancer frequently
develop metastasis to bone. Bone metastasis results in
intractable pain and high risk of pathologic fractures due to
osteolysis. The treatment of breast cancer patients with
bone metastases requires a multidisciplinary approach.
Radiotherapy is an established treatment for metastatic
bone pain. It may be delivered either as a localized low
dose treatment for localized bone pain or systemically for
more widespread symptoms. Bisphosphonates have been
shown to reduce morbidity and bone pain from bone
metastases when given to patients with metastatic bone
disease. In vivo studies indicate that early bisphosphonates
administration in combination with radiotherapy improves
remineralization and restabilization of osteolytic bone
metastases in animal tumor models. This review focused on
a brief discussion about biology of bone metastases, the
effects of radiotherapy and bisphosphonate therapy, and
possible mechanisms of combination therapy in metastatic
breast cancer patients.
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Introduction
Breast cancer is a common invasive cancer that affects
more than a million women annually worldwide, and bone
metastases are frequent in patients with advanced meta-
static disease [1]. Metastasis to spine, ribs, pelvis, and
proximal long bones are frequently seen pathological
lesions in advanced breast cancer, leading to debilitating
skeletal complications such as spinal cord compression,
hypercalcemia, osteolysis, and pathologic fracture. More-
over, it has been estimated that up to 50–90% of breast
cancer patients with bone metastases suffer from intracta-
ble bone pain [2]. Hence, due to the long clinical course
that breast cancer may follow, morbidity from bone
metastases also makes major demands on resources for
health care provision.
Biology of bone metastases
The normal bone is constantly remodeling, and this healthy
bone metabolic activity is characterized by two opposite
actions: the formation of new bone by osteoblasts and the
resorption of old bone by osteoclasts. The pathophysiology
of osteolysis is dependent on a breakdown of this coordi-
nation between osteoblasts and osteoclasts. Although most
cancers that metastasize to bone are a mixture of osteolytic
and osteoblastic, breast cancers tend to be primarily
osteolytic.
It is now becoming increasingly clear that the produc-
tion of locally acting osteoclastogenic and resorptive
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factors by both osteoblasts and stromal cells is dependent
on a number of molecular interactions between each other
and the breast cancer cells lodged in the bone marrow
microenvironment [3]. RANKL (the receptor activator of
NF-jB ligand) has been characterized as the key mediator of
osteoclast differentiation and activation. RANKL is
expressed by activated T cells, marrow stromal cells and
osteoblasts and binds to its receptor RANK, which is
expressed by osteoclast precursors, chondrocytes and
mature osteoclasts. The binding of RANKL on RANK pro-
motes osteoclast maturation and activation [4]. Moreover, it
affects the mature osteoclasts causing actin ring formation,
cytoskeletal rearrangements that precede bone resorption,
and activating mature osteoclasts to resorb bone [5].
Osteoprotegerin (OPG) acts as a decoy receptor antag-
onist for RANKL [6]. It is secreted mainly by osteoblastic
lineage and stromal cells. A balanced RANKL/OPG ratio is
essential for a normal bone turnover. It has been shown that
breast cancer cells-produced parathyroid hormone-related
peptide (PTHrP) induces the RANKL and suppresses the
OPG expression by osteoblasts and stromal cells within the
bone microenvironment [7]. These cause the imbalance
between the RANKL and OPG ratio that favors the for-
mation and activation of osteoclasts. In addition to
RANKL/OPG system, several chemokines and cytokines
such as interleukin-8 (IL-8), IL-11, tumor necrosis factor
alpha (TNF-a), and macrophage colony stimulating factor
(M-CSF) have been implicated in the stimulation of
osteoclast differentiation [8]. The resulting enhanced bone
resorption releases various cytokines and growth factors
[e.g. TGF-b (transforming growth factor beta), IL-6] from
the extracellular bone matrix and osteoclasts that further
promote tumor invasion and metastasis, thus maintaining a
vicious circle between osteoclasts and breast cancer cells
(Fig. 1). In addition to promoting invasion, and metastasis
of breast cancer, TGF-b secreted by the extracellular
bone matrix and osteoclasts suppresses late stages of
osteoblast differentiation [3]. It has been shown that met-
astatic breast cancer cells alter osteoblast adhesion, prevent
differentiation, and induce apoptosis, but fas/fas-ligand and
TNF-a, two common initiators of cell death, are probably
not involved in this aspect of the metastasis/bone cell axis
[9, 10]. Therefore, bone destruction in metastatic breast
cancer results from asynchronous bone turnover wherein
increased osteoclastic bone resorption is not accompanied
by a comparable increase in bone formation. In addition to
targeting the osteoblasts, it is clear that therapies that
repress osteoclast differentiation and target osteoclast sur-
vival would be of great benefit in repressing bone
destruction and slowing tumor progression in patients with
bone-metastatic breast cancer.
Radiotherapy
Radiotherapy has long been established as an effective
treatment for pain secondary to bone metastases, notably in
breast carcinoma. It is also effective for shorter or longer
time periods in the preservation of mobility and function,
maintenance of skeletal integrity, and preservation of
quality of life.
Radiotherapy can often achieve pain relief within
4–6 weeks in around 80% of patients treated [11]. Radio-
therapy is most effective when the disease is localized
allowing the highest dose to be delivered to the lesion. If
multiple lesions at multiple sites require therapy, side
effects, including particularly myelosuppression, may limit
the dose that can be delivered. The other purpose of
radiotherapy in breast cancer is to prevent local recurrence,
either as adjuvant therapy following conservative breast
Fig. 1 The biology of
osteolytic bone metastasis in
breast cancer. RANKL the
receptor activator of NF-jB
ligand, RANK RANKL receptor,
OPG osteoprotegerin, MCS-F
macrophage colony stimulating
factor, TNF-a tumor necrosis
factor alpha, IL-6 Interleukin-6,
TGF-b transforming growth
factor beta, PTHrP parathyroid
hormone-related peptide.
Adapted from Cicek et al. [3]
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surgery or as definitive treatment for locally advanced
inoperable disease [12].
Radiotherapy is quite effective in pain relief and bringing
about the remineralization of bone. Due to the loss of bone
microstructure, remineralization occurs mainly within the
fibrous scar tissue that fills the bone defects or along the
remaining bone trabeculae by apposition of woven bone.
Because bone microarchitecture is significantly correlated
with reduced bone stability and pathologic fractures,
increased bone density alone may not lead to a propor-
tionate increase in stability after successful radiotherapy
[13]. So, despite the maintenance of skeletal integrity and
the remineralization of bone lesions after radiotherapy,
fracture risk still can sustain [14]. However, in a small
nonrandomized study assessing the development of new
vertebral fractures in multiple myeloma patients, less ver-
tebral fractures have been observed in irradiated vertebrae
than in nonirradiated ones as assessed by MRI [15].
The precise mechanism of action by which radiation
results in metastatic pain relief remains uncertain. Radia-
tion alters cancer cell functions and causes a reduction in
the number of viable tumor cells within the radiation field
and in due course this would be expected to result in
shrinkage of the tumor bulk [16]. Then the removal of the
tumor from the bone enables osteoblastic repair, restoring
integrity of the damaged bone. However, certain features,
especially the lack of a dose–response relationship and
rapid pain relief, which may be seen especially after sys-
temic radiotherapy when relief within 24–48 h occurs in up
to 25% of patients make it unlikely that tumor shrinkage
itself is accounted for the pain relief [17]. The perceived
absence of a dose–response relationship also suggests that
tumor shrinkage may not be important and this would not
be expected with some of the very low doses, down to
4 Gy, which have been shown to cause pain relief [18].
Similarly no relation between pain relief and radiological
features, either osteoblastic or osteolytic, has been reported
[19]. Moreover, experimental studies revealed that sup-
pression of progressive osteoclast activity as measured by
urinary markers of bone degradation may correlate with
response to radiotherapy [20]. This supports that radiation
may have an analgesic effect through osteoclast inhibition,
which provides an insight into the bisphosphonate activity.
Bisphosphonates (BPs)
Bisphosphonates that bind preferentially to bone at sites of
active bone metabolism are released from the bone matrix
during bone metabolism and used successfully as powerful
inhibitors of increased bone resorption in several bone
diseases, including Paget’s disease of bone, osteoporosis,
hypercalcemia of malignancy, and tumor-associated bone
disease. Therefore, BPs are used to decrease skeletal-rela-
ted complications for a number of tumors including breast,
prostate and multiple myeloma, leading to improved
quality of life. Current views suggest that BPs may affect
differentiation and recruitment of osteoclast precursors or
alter the capability of mature osteoclasts to resorb bone by
altering the permeability of the osteoclast membranes to
small ions [21, 22]. Newer nitrogen-containing BPs, such
as zoledronic acid, pamidronate, and ibandronate, have a
unique mechanism of action and increased clinical activity
compared with the first-generation BPs, such as etidronate
and clodronate. In particular, the nitrogen-containing BPs
impede the mevalonate pathway of cholesterol synthesis
that is an essential pathway for osteoclast functions and
survival, and prevent protein prenylation in osteoclasts [23,
24]. The post-translation modification or prenylation of
small guanosine triphosphate-binding proteins, such as Ras
and Rho, require two isoprenoid lipid intermediates: far-
nesyl diphosphate and geranylgeranyl diphosphate [24].
Effective Ras signaling requires the attachment of Ras
proteins to the plasma membrane, a process initiated by the
enzyme farnesyl protein transferase [25]. Prevention of
prenylation occurs when the enzyme farnesyl diphosphate
synthase is inhibited by nitrogen-containing BPs, thus
limiting production of both farnesyl diphosphate and ger-
anylgeranyl diphosphate, which then inhibit osteoclast
activity [26].
In a study by Carteni et al. [27], it has been shown that
the breast cancer patients with newly diagnosed bone
metastases and treated with zoledronic acid had a low
incidence of skeletal-related events when compared with
patients who received placebo in randomized phase III
trials, and pain was decreased from baseline.
Antitumor effects of BPs
Preclinical studies suggest that BPs have direct antitumor
effects in vitro and can reduce skeletal tumor burden and
prevent the development of bone metastases in animal
models [28]. We have recently demonstrated that zoled-
ronic acid induces antiproliferative and apoptotic effects on
multiple myeloma cell lines in vitro, by activating protein
kinase C, and increases the extracellular calcium concen-
trations, these effects being augmented with dexamethasone
and thalidomide [29]. In addition, objective remission or
inhibition of disease progression has been reported in
patients with multiple myeloma who underwent pamidro-
nate treatment alone [30]. Recent data have shown that BPs
stimulate a subset of T-cells and have pronounced effects on
the immune system [31].
Bisphosphonates may exert their antimyeloma effect by
inhibiting release of bone marrow-derived growth factor,
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such as transforming growth factor b and insulin-like
growth factor into the marrow, by inducing apoptosis of
multiple myeloma cells, down-regulating production of
interleukin 6 from bone marrow stroma, and stimulating cd
T-cell-mediated antiplasma cell activity in the marrow [21,
31, 32]. In another study, we demonstrated that zoledronic
acid was able to increase disease-free survival in pristane-
induced plasmacytoma, a model with no direct bone
involvement, in BALB/c mice [33]. In that study, zoled-
ronic acid treatment markedly impeded intraperitoneal
plasmacytoma development. The treatment also decreased
the tumor burden and extramedullary tumor growth in mice.
Other studies have also suggested that BPs can inhibit
the adhesion of breast cancer cells to bone matrices and can
enhance the ability of antineoplastic agents to inhibit breast
cancer cell invasion [34, 35]. We have recently demon-
strated that zoledronic acid inhibited both cell growth and
proliferation, and also induced apoptosis on breast cancer
cells in vitro in a time- and dose-dependent manner [36].
Animal studies have demonstrated that pretreatment of
mice with two other potent BPs, risedronate and ibandro-
nate, before breast cancer cell inoculation caused a
significant reduction in tumor burden in bone [37]. Mundy
et al. [38] reported that the tumor burden in bone was
decreased by zoledronic acid in a dose-dependent manner
in an orthotropic mouse mammary tumor model.
BP and radiotherapy combination in breast cancer
Current trends in the treatment of human tumors are with
drug combination. This approach results in improved
responses as well as in the ability to use lower, less toxic
concentrations of the drugs. In clinical practice, metastatic
breast cancer patients would rarely be treated with BPs
alone, and may instead be given drug combinations such as
anthracyclines and taxoids. This notion, the synergistic
antitumor effect of zoledronic acid with other chemother-
apeutic agents, further supports the combined use of BP
and radiotherapy [39].
Both radiotherapy and BPs have effects on cellular
homeostasis, particularly osteoclast differentiation and
activity, around the bone metatasis. Radiation however is
non-selective in contrast to the BPs, resulting in wide-
spread cell damage affecting amongst others not only
osteoclasts but also osteoblasts and tumor cells. Through
their common action on osteoclast, a positive interaction
within an area of bone metastasis may be postulated which
will depend on the relative extent to which the two are
effective [11].
We recently showed that using the combination of
zoledronic acid and radiation always enhanced the growth
inhibition on breast cancer cells synergistically compared
with each agent alone [36]. The combination proved to be
true synergism rather than a simple additive effect, as
shown clearly by the calculated combination index (\1.0).
Likewise, Algur et al. [40] reported that zoledronic acid
induced cytotoxicity in human prostate and myeloma cell
lines in a synergistic manner when combined with radio-
therapy. The synergistic mechanism of zoledronic acid and
radiation, however, is currently unknown. We recently
showed an increase in the proportion of the cells in the
S-phase by flow cytometric analysis of zoledronic acid-
treated multiple myeloma cells, possibly due to a slower
progression through the S-phase or a block between the
S-phase and G2M-phase in the cell cycle [29]. This ability
of the BPs to arrest the cells in the G2M-phase or prolong
cell cycle progression raises the possibility of BPs as
potential cell cycle radiosensitizers since G2 and M cells
are more sensitive than cells within other cell cycle phases
[41]. Conversely, even radiosensitization by any agent
requires progression of cells through the cycle and accu-
mulation in G2M-phase, some studies show that apoptosis
is a predictor of the radiosensitization. These studies sug-
gest that accumulation of cells by any agent in a radiation-
sensitive phase of the cell cycle does not automatically
confer increased sensitivity to radiation [25, 42].
It has been shown that overexpression or transformation
of rodent or human cells by Ras results in cell lines that are
substantially more resistant to radiation than the parental
cells [43]. Conversely, inhibition of Ras activation resulted
in radiosensitization in both rodent cells transfected with
Ras and human tumor cells bearing endogenous mutations
in Ras [44]. The radiosensitizing effect of BPs could
therefore also be attributable to Ras signaling blockade by
depleting the cellular pools of both geranylgeranyl pyro-
phosphate and farnesyl pyrophosphate. Both prolonged
G2M accumulation concomitant with an increase in sus-
ceptibility to induction of apoptosis and Ras signaling
blockade may be associated with cellular mechanisms of
radiosensitization produced by BPs in tumor cells.
In the clinical setting, BPs are even more often com-
bined with radiotherapy for the treatment of patients with
metastatic bone disease since it is now recommended to
start BPs early in the management of metastatic bone dis-
ease [45, 46]. In this context, in vivo studies indicate that
early BP administration in combination with radiotherapy
in an animal tumor model improves remineralization and
restabilization of osteolytic bone metastases in the
sequential administration setting [14]. Although guidelines
from the American Society of Clinical Oncology (ASCO)
suggest that i.v. pamidronate or zoledronic acid may be
useful in the treatment of pain caused by bone metastases,
when used with concurrent systemic chemotherapy and/or
hormonal therapy, there is insufficient evidence to support
its role as adjunctive therapy to radiation therapy when no
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other systemic treatment is being used [46]. However,
promising clinical data indicated significant increases in
bone mass and bone formation in breast cancer patients
with bone metastases, who received long-term pamidronate
together with local radiation therapy [47].
Discussion
The major clinical problems that arise in breast cancer
patients relate to the enhanced bone loss commonly
occuring in these patients. As pain is the most frequently
reported symptom from patients with metastatic bone
disease, effective and rapid pain management is essential to
improve levels of functioning. Any therapeutic intervention
such as radiotherapy and bisphosphanate therapy or their
combination to alleviate pain improves the quality of life
and shortens the hospital stay of these patients. For patients
with painful or unstable bone metastases, radiotherapy
plays an important role, bringing about pain relief and
enabling the remineralization of bone lesions. Preclinical
evidences suggest that bisphosphanates may inhibit tumor
cell adhesion to bone, tumor growth, and angiogenesis. A
number of well designed, randomized clinical trials of
bisphosphanate therapy for breast cancer patients are cur-
rently under way. Moreover, due to the radiosensitizing
effect of bisphosphanates, combination of bisphosphanate
and standard palliative radiotherapy might improve the
latter’s effectiveness. For metastatic bone disease, com-
bining standard radiation treatment with bisphosphanates
might produce the same effect with a lower radiation dose
or lower fraction number, thus producing fewer side effects.
Bone-related complications in breast cancer patients result
from asynchronous bone turnover wherein increased
osteoclastic bone resorption is not accompanied by a com-
parable increase in bone formation. So, the future direction
for treatment of metastatic bone disease may lie in the
combination of inhibition of bone resorption and stimula-
tion of bone formation with new proteasome inhibitors
commonly used in myeloma patients to restore the balance
of bone remodeling in patients with breast cancer, and thus
protect against this destructive bone disease.
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